Efavirenz Articles
B-MS's earnings hit $714M in 1st-qtr
8 May 2006
B-MS and Gilead enter deal for HAART tablet
8 May 2006
Merck & Co cuts HIV AIDS drug prices 22%
20 March 2006
Mixed data from S-P's vicriviroc in HIV study
20 February 2006
Good efficacy for Gilead Sci's ARV combo
30 January 2006
Stock Commentary - New York week to Jan 9
16 January 2006
Gilead/B-MS' HIV combo drug is bioequivalant
16 January 2006
Stock Commentary - New York week to Aug 15
22 August 2005
Gilead's Truvada fails bioequivalence study
22 August 2005
ARV price cuts agreed for Latin America
15 August 2005
Gilead's Truvada HIV combo not bioequivalent
15 August 2005
Newer, pediatric, second-line ARVs "cost up to 12 times more than first-line drugs in LDCs"
11 July 2005
Brazil license request to HIV/AIDS drugmakers
28 March 2005
South Africa awards ARV drug tenders
14 March 2005
Gilead reports 48-wk data from HIV study
14 February 2005
B-MS and Gilead set up JV to market triple AIDS drugs
10 January 2005
South African TAC "may seek efavirenz license"
22 November 2004
Pharma acts on US fast- track plan for FDCs
24 May 2004
20% pharma sales rise boosts B-MS profits
9 February 2004
Gilead starts Viread/Emtriva combi study
18 August 2003
Gilead's Emtriva shows efficacy at 60 wks
28 July 2003
Activists fire shot at GSK over Trizivir study
17 March 2003
Viramune as good as more costly Sustiva
24 February 2003
S African Minister
17 February 2003
Positive Ph III data with Triangle's emtricitabine
17 February 2003
Triangle's Coviracil trial "un-blinded"
5 August 2002
WHO "essential list" of malaria, AIDS drugs
6 May 2002
BI's tipranavir effective in resistant HIV
11 March 2002
B-MS/Sanofi withdraw Avapro filing
11 February 2002
Brazil to step up HIV/ AIDS vaccine R&D
14 January 2002
Initial therapy with Viracept may avoid emergence of HIV "superbugs"
24 December 2001
Merck "will cut AIDS drug prices no further"
28 November 2001
Glead's Viread for HIV set for launch in USA "within days"
29 October 2001
Merck & Co Caribbean AIDS drug price cuts
29 August 2001
Cipla drops HIV/AIDS cocktail price in India
13 July 2001
DuPont's Sustiva tops PI therapy over 3 years
10 July 2001
BI's tipranavir effective as HIV salvage regimen
10 July 2001
New data for Viracept as first-line therapy
15 June 2001
Brazil prepares to make Roche AIDS drug
23 May 2001
DuPont's once-daily Sustiva filed in USA
9 April 2001
Merck & Co cuts AIDS drug prices in Brazil
2 April 2001
Merck & Co warning to Brazil over patent
27 March 2001
Merck & Co, B-MS cut drug prices further
20 March 2001
Merck & Co cuts AIDS drug prices in Romania
13 March 2001
Cuba backs Brazil in AIDS drug patent row
7 March 2001
PhRMA warns of pressure to bring reduced HIV/AIDS drug prices to USA
14 February 2001
Brazil challenge to USA over AIDS drugs
6 February 2001
Uganda/Merck & Co agree HIV drug price cuts
22 December 2000
DuPont looking to spin-off or sell pharmaceutical business
18 December 2000
First cheap HIV drugs for Senegal
26 October 2000
Gilead Sciences boosted on tenefovir DF resistance data
25 October 2000
Indian firms to launch new drugs this fiscal year
29 August 2000
DuPont's next-generation NNRTIs
20 July 2000
Lopinavir a "therapeutic drug of interest"
20 July 2000
US 1st-quarter results continue to flow in
3 May 2000
New data with Triangle's emtricitabine
3 February 2000
DuPont's Sustiva combo effective in children
16 December 1999
Sustiva, Combivir "beat HIV non-compliance"
13 October 1999
European launches for DuPont's Sustiva
3 June 1999
Sustiva cleared in Canada for HIV
29 March 1999
-DuPont's Sustiva recommended for approval in EU
11 March 1999
Sustiva-based HIV therapy assessed
18 February 1999
Low compliance could fuel AIDS epidemic
26 January 1999
Existing Opportunities In The New HIV/AIDS Treatment Paradigm
16 November 1998
First Approval Of DuPont's Sustiva In USA
21 September 1998
Stock Commentary New York
23 July 1998
Agouron Shopping For HIV Portfolio
1 July 1998
DuPont Merck Files For Sustiva Approval
18 June 1998
New Drugs May Address HIV In Brain
15 June 1998
Sustiva and T-20 Tested In Combination
25 March 1998
DuPont Merck To File Sustiva NDA Soon
5 February 1998
Combo Therapy With DuPont Merck's Sustiva
20 October 1997
NDA Filed For New Soft-Gel Saquinavir
9 October 1997
DuPont Merck's Sustiva, New Findings
17 September 1997
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
